AGIOS PHARMACEUTICALS, INC. Insider Trading for February 2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AGIOS PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in AGIOS PHARMACEUTICALS, INC. for February 2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hirsch Andrew | Chief Financial Off ... | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hirsch Andrew | Chief Financial Off ... | Option Exercise | A | 58.86 | 40,000 | 2,354,400 | 40,000 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | A | 58.86 | 40,000 | 2,354,400 | 40,000 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | A | 0.00 | 2,074 | 0 | 2,074 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | A | 58.86 | 8,295 | 488,244 | 8,295 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Option Exercise | A | 0.00 | 8,324 | 0 | 8,324 | |
| Feb 26 2019 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Option Exercise | A | 58.86 | 45,719 | 2,691,020 | 45,719 | |
| Feb 25 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | M | 0.00 | 3,300 | 0 | 0 | |
| Feb 25 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Payment of Exercise | F | 56.33 | 1,016 | 57,231 | 2,796 | 3.8 K to 2.8 K (-26.65 %) |
| Feb 25 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Buy | M | 0.00 | 3,300 | 0 | 3,812 | 512 to 3.8 K (+644.53 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Option Exercise | M | 0.00 | 8,125 | 0 | 16,250 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Payment of Exercise | F | 58.03 | 2,471 | 143,392 | 89,503 | 92 K to 89.5 K (-2.69 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Schenkein David P | Director | Buy | M | 0.00 | 8,125 | 0 | 91,974 | 83.8 K to 92 K (+9.69 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hoerter Steven L. | Chief Commercial Of ... | Option Exercise | M | 0.00 | 2,750 | 0 | 5,500 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hoerter Steven L. | Chief Commercial Of ... | Payment of Exercise | F | 58.03 | 1,040 | 60,351 | 10,941 | 12 K to 10.9 K (-8.68 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hoerter Steven L. | Chief Commercial Of ... | Buy | M | 0.00 | 2,750 | 0 | 11,981 | 9.2 K to 12 K (+29.79 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hirsch Andrew | Chief Financial Off ... | Option Exercise | M | 0.00 | 2,750 | 0 | 5,500 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hirsch Andrew | Chief Financial Off ... | Payment of Exercise | F | 58.03 | 821 | 47,643 | 12,374 | 13.2 K to 12.4 K (-6.22 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Hirsch Andrew | Chief Financial Off ... | Buy | M | 0.00 | 2,750 | 0 | 13,195 | 10.4 K to 13.2 K (+26.33 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Option Exercise | M | 0.00 | 2,750 | 0 | 5,500 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Payment of Exercise | F | 58.03 | 818 | 47,469 | 7,195 | 8 K to 7.2 K (-10.21 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Bowden Christopher | Chief Medical Offic ... | Buy | M | 0.00 | 2,750 | 0 | 8,013 | 5.3 K to 8 K (+52.25 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Biller Scott | Chief Scientific Of ... | Option Exercise | M | 0.00 | 2,750 | 0 | 5,500 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Biller Scott | Chief Scientific Of ... | Payment of Exercise | F | 58.03 | 876 | 50,834 | 26,511 | 27.4 K to 26.5 K (-3.20 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Biller Scott | Chief Scientific Of ... | Buy | M | 0.00 | 2,750 | 0 | 27,387 | 24.6 K to 27.4 K (+11.16 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Option Exercise | M | 0.00 | 790 | 0 | 1,580 | |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Payment of Exercise | F | 58.03 | 278 | 16,132 | 512 | 790 to 512 (-35.19 %) |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Buy | M | 0.00 | 790 | 0 | 790 | 0 to 790 |
| Feb 20 2019 | AGIO | AGIOS PHARMACEUTIC ... | Alenson Carman | Principal Accountin ... | Sell | S | 76.45 | 152 | 11,620 | 0 | 152 to 0 (-100.00 %) |
| Feb 05 2019 | AGIO | AGIOS PHARMACEUTIC ... | FOUSE JACQUALYN A | Chief Executive Off ... | Option Exercise | A | 0.00 | 42,695 | 0 | 42,695 | |
| Feb 05 2019 | AGIO | AGIOS PHARMACEUTIC ... | FOUSE JACQUALYN A | Chief Executive Off ... | Option Exercise | A | 53.87 | 350,346 | 18,873,139 | 350,346 |